Last reviewed · How we verify

NCT04237155: SOUMO

French Source-monitoring Task

Status unknown NA Last updated 24 March 2022
What this trial tests

NA trial testing Questionnaire in Schizophrenia in 120 participants. Status unknown.

Timeline
7 February 2020
Primary endpoint
1 February 2023
1 February 2024

Quick facts

Lead sponsorHôpital le Vinatier
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment120
Start date7 February 2020
Primary completion1 February 2023
Estimated completion1 February 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Hôpital le Vinatier — full company profile →

Who can join

Adults 18 to 45, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Source-monitoring is a cognitive process that refers to the ability to remember the source of an information. Source-monitoring processes are usually studied using experimental behavioral tasks. These tasks, which are very heterogeneous, are not all available in French and, for the most part, cannot be used in neuroimaging protocols. The aim of this project is to develop an experimental task which allows the measurement of source-monitoring performances, and which is adapted to neuroimaging protocols in a French-speaking population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

Other Hôpital le Vinatier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04237155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing